EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 19, 2025

Primary Completion Date

August 18, 2026

Study Completion Date

August 18, 2031

Conditions
Nasopharyngeal Cancinoma (NPC)
Interventions
DRUG

Valganciclovir Hydrochloride Tablets

Valganciclovir hydrochloride tablets will be administered at 900 mg twice daily from day 1 to day 14, followed by 450 mg twice daily from day 15 to day 20, for a total of 3 cycles.

DRUG

gemcitabine, cisplatin, and PD-1 antibody

"Gemcitabine 1000 mg/m² will be administered intravenously on days 1 and 8; cisplatin 80 mg/m² intravenously on day 1; and PD-1 antibody intravenously on day 1. Each cycle is 21 days in duration, and treatment will be administered for a total of 4 to 6 cycles.~Following completion of the 4 to 6 cycles, patients will continue PD-1 antibody maintenance therapy (every 3 weeks) for up to two years or until disease progression, unacceptable toxicity, initiation of a new anticancer therapy, withdrawal of informed consent, or death."

Trial Locations (1)

510060

Sun Yat-sen Universitty Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER